Merck KGaA

MRK

DE0006599905

Pharmaceuticals

Market Closed - Xetra Other stock markets 11:35:06 2024-07-12 am EDT			5-day change	1st Jan Change
154.2 ^EUR	+0.59%		+1.08%	+7.04%

Jul. 10	Merck KGaA: share price down, analyst lowers target	CF
Jul. 10	MERCK KGAA : UBS lowers price target	CF

MERCK KGAA : Gets a Neutral rating from NorldLB

January 06, 2021 at 08:56 am EST

Analyst Thorsten Strauß from NorldLB research gives the stock a Neutral rating.

Latest news about Merck KGaA

Merck KGaA: share price down, analyst lowers target	Jul. 10	CF
MERCK KGAA : UBS lowers price target	Jul. 10	CF
UBS lowers target for Merck KGaA to 178 euros - 'Buy'	Jul. 10	DP
MERCK KGAA : UBS keeps its Buy rating	Jul. 10	ZD
Dawn Health and Merck Collaborate to Support Growth Disorders Care	Jul. 01	CI
Chemicals collective agreement: Bonus days for union members	Jun. 27	DP
Chemicals collective bargaining agreement: extra day for trade unionists	Jun. 27	DP
Chemical industry wage partners seek solution before the end of the peace period	Jun. 25	DP
German Stocks Fall Tuesday	Jun. 25	DJ
Market Update-Europe closes lower in a session marked by a wait-and-see attitude	Jun. 25	RE
Global markets live: UBS, Boeing, AT&T, Rivian, Nvidia, Tesla...	Jun. 25
MERCK KGAA : Barclays cuts its target price	Jun. 25	CF
MERCK KGAA : Gets a Neutral rating from Bernstein	Jun. 25	ZD
MERCK KGAA : failure in head and neck cancer trial	Jun. 25	CF
UBS reiterates Merck KGaA at 'Buy' - Target 186 euros	Jun. 25	DP
Next pharmaceutical study flop for Merck KGaA - share price collapses	Jun. 25	DP
European shares fall as Airbus hammers aerospace shares, tech slips	Jun. 25	RE
Merck KGaA shocks investors with end to cancer drug program	Jun. 25	DP
Merck KGaA Shares Drop After Canceled Late-Stage Cancer Drug Study	Jun. 25	DJ
FTSE 100 edges up but mood tetchy amid US tech woe	Jun. 25	AN
MERCK KGAA : UBS maintains a Buy rating	Jun. 25	ZD
Shares Frankfurt opening: Airbus weighs on Dax with profit warning	Jun. 25	DP
Merck KGaA shares plunge after cancer drug hopeful fails	Jun. 25	RE
European shares open lower on Airbus, tech drag	Jun. 25	RE
Barclays lowers target for Merck KGaA to 195 euros - 'Overweight'	Jun. 25	DP

Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - solutions and products for scientific and biotechnological research (44.2%); - pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc. Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).

Sector

Pharmaceuticals

Calendar

2024-07-31 - Q2 2024 Earnings Call

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

MERCK : A lower starting point for future growth

May 27, 2024 at 03:36 am EDT

Merck KGaA : A European big pharma with positive momentum

January 20, 2023 at 05:51 am EST

More Strategies

Ratings for Merck KGaA

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

154.2 EUR

Average target price

183 EUR

Spread / Average Target

+18.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
MERCK KGAA	+7.04%	73.13B
KYOWA KIRIN CO. LTD.	+31.10%	10.38B
YUHAN CORPORATION	+37.94%	5.16B
SK BIOPHARMACEUTICALS CO., LTD.	-17.33%	4.73B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+21.49%	3.81B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+24.92%	2.26B
BETTA PHARMACEUTICALS CO., LTD.	-36.84%	1.88B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-43.31%	1.77B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B
SUPERNUS PHARMACEUTICALS, INC.	-1.11%	1.57B

Specialty & Advanced Pharmaceuticals

Merck KGaA

Equities

MRK

DE0006599905

Pharmaceuticals

MERCK KGAA : Gets a Neutral rating from NorldLB

Latest news about Merck KGaA

Chart Merck KGaA

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Merck KGaA

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals